Navigation Links
YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Date:5/28/2009

MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with head and neck cancer conducted by Biocon Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida from May 29 to June 2, 2009.

The poster entitled "A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer (abstract # 6041)" will be presented in the Head and Neck Cancer general poster session on Monday, June 1 from 8:00AM until 12:00PM on Level 2 in West Hall C.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemorad
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Paragon Development Systems is poised for significant growth with ... the company's 24/7 service desk, the company's founder said ... IT infrastructure services provider, officially unveiled its new Madison ... 361 Blettner Blvd. in June. , , The ...
... and other communications services will be among the subjects ... nine western Wisconsin counties discuss economic development. , ,It ... , which will build upon discussions at a December ... process are Barron, Clark, Chippewa, Dunn, Eau Claire, Pepin, ...
... opportunity to define public discourse over nanotechnology, if they ... technology, a University of Wisconsin-Madison journalism professor says. , ... going to come to you. You have to take ... where people look," says Dietram Scheufele, who conducted one ...
Cached Biology Technology:PDS sees Madison facility as launchpad for growth 2PDS sees Madison facility as launchpad for growth 3Telecom issues are among focus of upcoming western Wisconsin conference 2Telecom issues are among focus of upcoming western Wisconsin conference 3UW study examines public attitudes on nanotechnology 2
(Date:4/17/2014)... stem cell therapies to cure a variety of diseases ... based on cell surface markers. Researchers from the Finnish ... highly expressed in a type of stem cells derived ... an article in BioResearch Open Access , a ... article is available free on the BioResearch ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
(Date:4/17/2014)... cells in bone marrow need to produce hydrogen sulfide ... according to a new study from the Center for ... Dentistry of USC. , Professor Songtao Shi, principal investigator ... produced by the cells governs the flow of calcium ... signals that results in osteogenesis, or the creation of ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... Interventional Radiology ,s quality and influence has remained consistently high ... impact factor to 2.217 in 2008 ranks JVIR in the ... journals, according to results from the Thomson Reuters Journal Citation ... its impact, the Society of Interventional Radiology is now offering ...
... NYU and NYU School of Medicine received a $29.4 ... Institutes of Health (NIH) to establish a University-wide Clinical & ... City Health and Hospitals Corporation (HHC). The funding is ... the lab to the patient to the community and to ...
... of Arago, an international team of scientists has analyzed the dental ... heidelbergensis . It is the first time that an analytical method ... archaeological sites. The key is the last food that these hominids ... groups of hominids and how long they spent in caves or ...
Cached Biology News:Journal of Vascular and Interventional Radiology increases impact, international reach 2Journal of Vascular and Interventional Radiology increases impact, international reach 3$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 2$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 3$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 4The last supper of the hominids establishes the times they lived at the sites 2
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
Standard Fluka For microscopy (Hist.) redox indicator...
Biology Products: